Subsequently, crizotinib was re-administered at the initial dose. Median PFS was significantly higher with crizotinib From [ 26 ]. Data are available from patients enrolled and treated up to February , of whom were evaluable for response. A Phase 2 Study. There is evidence that some patients can continue to derive benefit from crizotinib therapy beyond RECIST-defined progression.
Clinical course after administration of crizotinib. The ITT population in PROFILE comprised patients randomised to crizotinib and to chemotherapy who at the time of the primary analysis had been followed up for a median of View large Download slide. The duration of crizotinib treatment in our case is superior to the median progression-free survival of 7. There was no recurrence of the esophageal symptoms.
Receive exclusive offers and updates from Oxford Academic. Crizotinib is used worldwide for the treatment of ALK-positive NSCLC; however, there is increasing accumulation of data with regard to its potential adverse events, which may be severe.
Shaw et al 5 reported that ALK-positive NSCLC patients exhibited a longer overall survival following crizotinib administration as second- or third-line therapy in a retrospective case-matched analysis.
XALKORI case study
Reprinted from [ 21 ], with permission from Elsevier. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.
National Center for Biotechnology InformationU. However, ophthalmologic or neurologic evaluation may be necessary for patients whose visual disturbances persist or worsen during treatment.
These patients had significantly longer overall survival from the time of progression median Xalkorri this report, the successful management of crizotinib-induced neutropenia by caae reduction of crizotinib in a patient with ALK-positive non-small cell lung cancer is described.
Adenocarcinoma cells were detected by cytological examination of the pleural effusion. Furthermore, this clinical trial confirmed that the incidence of severe neutropenia was higher in the high-dose group than in the low-dose group. Patients receiving crizotinib also had a significantly longer time to worsening of lung cancer symptoms cough, dyspnoea or chest pain compared with chemotherapy HR: The CNS is one of the principal sites of disease progression for patients receiving crizotinib therapy [ 31 ].
Successful treatment of crizotinib-induced dysgeusia by switching to alectinib in ALK-positive non-small cell lung cancer. Four months later the CEA levels were within the normal range and a CT examination revealed no evidence of recurrence.
In subsequent phase III studies, crizotinib was shown to be generally well tolerated and associated with significant improvements in efficacy and QoL in both previously treated and previously untreated patients. However, there are currently few reports of detailed clinical experience and management of severe neutropenia in these patients.
XALKORI case study | TIGCRU Insight
Firstly, ALK positivity is associated with lower levels of thymidylate synthase, one of the targets of pemetrexed This treatment was continued for 36 months 34 cycles Fig. It furthers the University’s objective of excellence in research, scholarship, and education by publishing worldwide.
Although crizotinib was associated with potentially fatal pneumonitis or wtudy lung disease ILD in a few number of patients [ 2627 ], such events may be related to NSCLC or previous treatment such as radiotherapy rather than to crizotinib [ 34 ]. Looking for your next opportunity?
Published online Jan The patient provided their consent for their participation in the study. Patients whose tumours express ALK fusion proteins are eligible for treatment with ALK inhibitors, the first of which was crizotinib. Eight days later, the patient was unable to eat or drink.
View large Download slide. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer AFJG: Interestingly, patients in the pemetrexed group achieved greater PFS than those in the docetaxel group, consistent with previous studies demonstrating a greater sensitivity to pemetrexed in patients with ALK -positive versus wild-type tumours [ 2829 ].
Crizotinib for the treatment of ALK-rearranged non-small cell lung cancer: A year-old woman was admitted to our hospital with a left pleural effusion.
In both phase III studies, most adverse dalkori were of grade 1 or 2 severity [ 2627 ]. This article has been cited by other articles in PMC. Journal List Case Rep Oncol v. Bone health in childhood cancer: Non-small-cell lung cancer NSCLC is associated with a poor prognosis and low survival rates, providing a strong rationale for the development of new treatment options.